MEAGHAN NELSON: Open Payments
NPI 1780219618 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,327 in 124 payments from 18 companies in 2025. Trend: 2023 $400 · 2024 $1,771 · 2025 $2,327
Food & beverage: $2,327
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 55 | $787 |
| Madrigal Pharmaceuticals | 11 | $362 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $261 |
| PFIZER INC. | 9 | $137 |
| Ipsen Biopharmaceuticals, Inc | 3 | $117 |
| Celltrion USA Inc. | 6 | $114 |
| Regeneron Healthcare Solutions, Inc. | 6 | $97 |
| GlaxoSmithKline, LLC. | 1 | $95 |
| GENZYME CORPORATION | 5 | $94 |
| Ardelyx, Inc. | 3 | $59 |
Products named: RINVOQ, REZDIFFRA, SKYRIZI, ENTYVIO, DUPIXENT, VEGZELMA, IQIRVO, VELSIPITY.
Industry payments across ID — which companies pay providers there.
